Acadia Pharmaceuticals (ACAD) Stake Decreased by Macquarie Group Ltd.

Macquarie Group Ltd. reduced its holdings in Acadia Pharmaceuticals (NASDAQ:ACAD) by 90.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,200 shares of the biopharmaceutical company’s stock after selling 71,610 shares during the quarter. Macquarie Group Ltd.’s holdings in Acadia Pharmaceuticals were worth $217,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of ACAD. Nationwide Fund Advisors boosted its position in shares of Acadia Pharmaceuticals by 42.4% during the third quarter. Nationwide Fund Advisors now owns 38,350 shares of the biopharmaceutical company’s stock valued at $1,445,000 after purchasing an additional 11,410 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Acadia Pharmaceuticals by 3.1% during the third quarter. New York State Common Retirement Fund now owns 214,800 shares of the biopharmaceutical company’s stock valued at $8,092,000 after purchasing an additional 6,500 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Acadia Pharmaceuticals by 7.7% during the third quarter. Bank of New York Mellon Corp now owns 452,696 shares of the biopharmaceutical company’s stock valued at $17,053,000 after purchasing an additional 32,418 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Acadia Pharmaceuticals by 17.8% during the third quarter. Legal & General Group Plc now owns 39,604 shares of the biopharmaceutical company’s stock valued at $1,492,000 after purchasing an additional 5,973 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Acadia Pharmaceuticals by 8.6% during the third quarter. Schwab Charles Investment Management Inc. now owns 422,605 shares of the biopharmaceutical company’s stock valued at $15,920,000 after purchasing an additional 33,478 shares in the last quarter. Hedge funds and other institutional investors own 96.24% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, Director Daniel B. Soland acquired 7,000 shares of the stock in a transaction on Thursday, March 1st. The stock was acquired at an average price of $23.91 per share, for a total transaction of $167,370.00. Following the completion of the purchase, the director now owns 2,000 shares of the company’s stock, valued at $47,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Glenn Baity sold 36,558 shares of Acadia Pharmaceuticals stock in a transaction on Monday, January 29th. The shares were sold at an average price of $32.39, for a total value of $1,184,113.62. Following the transaction, the executive vice president now owns 83,734 shares of the company’s stock, valued at approximately $2,712,144.26. The disclosure for this sale can be found here. 22.25% of the stock is currently owned by insiders.

Shares of NASDAQ:ACAD opened at $18.90 on Monday. Acadia Pharmaceuticals has a 12-month low of $15.74 and a 12-month high of $41.20.

Acadia Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.03. The business had revenue of $43.56 million during the quarter, compared to analysts’ expectations of $45.30 million. Acadia Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 231.71%. equities research analysts predict that Acadia Pharmaceuticals will post -1.82 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on the company. BidaskClub lowered Acadia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 11th. Zacks Investment Research lowered Acadia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. JPMorgan Chase set a $50.00 price target on Acadia Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, April 10th. Finally, ValuEngine lowered Acadia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, March 23rd. Three analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $49.50.

TRADEMARK VIOLATION WARNING: This story was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2018/04/16/acadia-pharmaceuticals-acad-stake-decreased-by-macquarie-group-ltd.html.

About Acadia Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acadia Pharmaceuticals (NASDAQ:ACAD).

Institutional Ownership by Quarter for Acadia Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for Acadia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply